论文部分内容阅读
目的观察吉非替尼治疗老年晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法12例老年晚期无手术及化疗指征的NSCLC患者给予吉非替尼250mg口服,每天1次,直至病情进展或出现不可耐受的不良反应,评价近期疗效、生存期、生活质量及不良反应。结果完全缓解(CR)2例,部分缓解(PR)5例,稳定(SD)3例,进展(PD)2例,有效率为41.67%,临床受益率为58.33%;中位无疾进展时间为6个月,中位生存期为13个月,1年生存率为63.23%;生活质量明显改善者占66.67%;药物不良反应多为Ⅰ～Ⅱ度皮疹及腹泻。结论吉非替尼应用于老年晚期不能手术和化疗的NSCLC患者的治疗,疗效确切,不良反应轻微,可明显改善患者的生活质量。
Objective To observe the efficacy and adverse reactions of gefitinib in elderly patients with advanced non-small cell lung cancer (NSCLC). Methods Twelve elderly patients with advanced non-surgical and chemotherapy-indicated NSCLC were given gefitinib 250 mg orally once a day until the condition progressed or intolerable adverse reactions were evaluated. The short-term efficacy, survival time, quality of life and adverse reactions were evaluated. . Results There were 2 cases of complete remission (CR), 5 cases of partial remission (PR), 3 cases of stable (SD), and 2 cases of progressive (PD). The effective rate was 41.67%. The clinical benefit rate was 58.33%; For 6 months, the median survival period was 13 months, the one-year survival rate was 63.23%; the quality of life was significantly improved by 66.67%; the adverse drug reactions were mostly I-II degree rashes and diarrhea. Conclusion Gefitinib is used for the treatment of NSCLC patients with advanced and inoperable chemotherapy in the elderly. The curative effect is definite, and the adverse reactions are slight. The quality of life of patients can be significantly improved.